Rays Power Infra announced closure of INR 127 Crore Equity Capital Fund Raise - "Mother's Embrace" A Photography Exhibition will be displayed by Renowned Photographer Devendra Naik at Jehangir Art Gallery in Mumbai - DAM Capital Advisors collects Rs 251 cr from Anchor Investors - Blackstone backed Ventive Hospitality Limited raises ₹ 719.55 Crores from 26 anchor investors at the upper end of the price band at ₹643 per equity share - The Inventurus Knowledge Solutions Limited listing ceremony held at NSE today - “ENCOUNTER WITH THE MOMENT” An Exhibition of Photographs by Gurdeep Dhiman at Jehangir Art Gallery in Mumbai - VENTIVE HOSPITALITY LIMITED ANNOUNCED ITS Rs. 16,000 MILLION INITIAL PUBLIC OFFERING (IPO) TO OPEN ON FRIDAY, DECEMBER 20, 2024 Sets Price Band fixed at Rs. 610 to Rs. 643 per equity share of face value of Rs. 1 each - Dr Agarwals Eye Hospital, Chembur, launches advanced laser system for precise and bladeless corneal surgery, Renowned actress Saiee Manjrekar inaugurates the state-of-the-art WaveLight FS200 Femtosecond Laser System - DAM Capital Advisors Limited announced its initial public offering (IPO) to open on Thursday, December 19, 2024 Sets Price Band fixed at ₹ 269/- per equity share to ₹ 283/- per equity share of the face value of ₹2 each - TRANSRAIL LIGHTING LIMITED ANNOUNCED ITS INITIAL PUBLIC OFFERING (IPO) TO OPEN ON THURSDAY, DECEMBER 19, 2024 Sets Price Band has been fixed at ₹ 410.00 to ₹ 432.00 per equity share, of face value ₹2 each - CONCORD ENVIRO SYSTEMS LIMITED ANNOUNCED ITS INITIAL PUBLIC OFFERING (IPO) TO OPEN ON THURSDAY DECEMBER 19, 2024 Sets Price Band fixed at ₹ 665 to ₹ 701 per equity share of face value of ₹5 each

Apollo, Navi Mumbai Launches Advanced Isotope Radionuclide Therapy at Thyroid Cancer Symposium

Radionuclide therapy, a minimally invasive targetted therapy, can be used for treating both cancerous and non-cancerous conditions for improved treatment outcomes

Navi Mumbai, 11 April 2023 (GNI): Apollo Cancer Centres, Navi Mumbai launched the advanced radionuclide therapy for treatment of thyroid cancer at a symposium. The symposium, addressed by various national and international experts, highlighted the latest advancements in the field of thyroid surgery and the role of therapy in offering a precise and targeted approach to cancer treatment for an improved quality of life for cancer patients. 

Radionuclide Therapy (RNT) is a new treatment option in the multidisciplinary management of cancer that involves using radiation to target and destroy cancer cells. It is a minimally invasive procedure and is effective in targeting and destroying cancer cells without damaging the surrounding healthy tissue, thus improving outcomes and quality of life for patients. RNT can be used for treating both malignant cancers and some non-cancer conditions.

Dr. Anil D’Cruz, Director of Oncology, Consultant Surgical Oncology Apollo Hospitals, Navi Mumbai, said, “Targeted therapies, such as radionuclide-based therapy is a modern technology that like chemotherapy reach cells throughout the body by traveling in the bloodstream. However, unlike chemotherapy, the radioactive substances target only diseased cells and thus, reduce the potential side effects. By targeting and destroying cancer cells with minimal side effects, it can be an effective treatment for a variety of cancers, including liver cancer, thyroid cancer, prostate cancer and neuroendocrine tumours.

Dr. Anand Zade Head, Department of Nuclear Medicine, Apollo Cancer Centres, Navi Mumbai, said, “The advancements in medical technology have led to a dramatic surge in the development and availability of new cancer treatments. Radionuclide Therapy has emerged as a powerful tool in the fight against cancer that can be delivered in a variety of ways, including through intravenous injection of a radioactive drug, or a radioactive material placed directly in the area of cancer. The radiation is then absorbed by the cancer cells, destroying them.

Mr. Santosh Marathe, Regional CEO – Western Region, Apollo Hospitals, said, Mr. Santosh Marathe, Regional CEO – Western Region, Apollo Hospitals, said, “The launch of advanced isotope radionuclide therapy represents a major step forward in the battle against cancer, offering new hope for patients and their families. This cutting-edge treatment will enable patients to receive better care and treatment and will help us to continue to push the boundaries of what is possible in the fight against cancer. Apollo Cancer Care Centres, at Navi Mumbai provides all comprehensive treatment modalities at the Hospital including Organ specific Senior Consultants, latest technology including Da Vinci Robotics, rehab services and very advanced critical care unit. Almost 15% of cancer patients treated at the unit come from peripheral areas of Maharashtra and beyond,” stated in the press release.ends GNI SG

Be the first to comment on "Apollo, Navi Mumbai Launches Advanced Isotope Radionuclide Therapy at Thyroid Cancer Symposium"

Leave a comment

Your email address will not be published.


*